Press Releases XBiotech Inc.

Equities

XBIT

CA98400H1029

Delayed Nasdaq Other stock markets 16:13:29 20/06/2024 BST			5-day change	1st Jan Change
5.066 ^USD	-3.68%		-19.84%	+26.66%

06-18	XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer	CI
05-10	XBiotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer	06-18	GL
XBiotech: Q1 Earnings Snapshot	05-10	AQ
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	01-04	GL
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	01-04	GL
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	01-04	AQ
Dr. Alan Kivitz to Chair XBiotech s Natrunix Program in Rheumatoid Arthritis	11-15	AQ
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	11-14	GL
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	11-14	AQ
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	26/09/23	GL
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	26/09/23	AQ
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/08/23	GL
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/08/23	AQ
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis Clinical Trial	09/08/23	AQ
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial	08/08/23	GL
XBiotech Inc. - FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients	23/05/23	AQ
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients	22/05/23	GL
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients	22/05/23	AQ
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares	17/05/23	GL
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares	17/05/23	AQ
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	17/04/23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases XBiotech Inc.

Equities

XBIT

CA98400H1029

Press Releases

Filters